Many South Asian people probably need pre-diabetes care

Citation for published version:
Bhopal, R & Fischbacher, CM 2002, 'Many South Asian people probably need pre-diabetes care' BMJ, vol 325, no. 7370, pp. 965. DOI: 10.1136/bmj.325.7370.965/a

Digital Object Identifier (DOI):
10.1136/bmj.325.7370.965/a

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
BMJ

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Prevention and cure of type 2 diabetes

General practitioners are treating more cases of diabetes

Editor—Most studies measuring the prevalence of diabetes have been carried out in one locality and have generally measured point prevalences. Hence, although the prevalence of diabetes in England and Wales is increasing, the time trend data on prevalence and future projections based on sound data are both lacking. We recently estimated the prevalence of diabetes in England and Wales between 1994 and 1998 using data from 210 general practices with a combined list size of 1.2 million.1

We found that the overall prevalence of diabetes during this period increased from 1.90% to 2.43% in males and from 1.68% to 2.04% in females. This striking increase in the prevalence of diabetes in primary care is likely to be due to a combination of factors, including better case ascertainment, rising rates of obesity, an ageing population, and an increase in both the size and average age of the ethnic minority population. Overall, 29%, 48%, and 24% of males with diabetes and 26%, 48%, and 26% of females with diabetes were treated by diet, oral hypoglycaemic drugs alone, and insulin respectively.

We estimated around 1.15 million people had a diagnosis of diabetes mellitus in England and Wales in 1998. If the age specific prevalence of diabetes increases by a modest 30% over the next 25 years (less than predicted by many authorities), then the number of people with diabetes will increase by 70%, to 1.96 million by 2023. If age specific prevalence increases by more than 30%, then the increase in the number of cases will be even larger.

Our findings illustrate the potential size of the diabetes epidemic facing England and Wales. The epidemic will have major implications for the NHS, which will have to provide diabetic services for these patients, as well as deal with the clinical and psychosocial complications resulting from diabetes. We therefore reinforce the need to tackle the underlying causes of this epidemic, particularly by increasing levels of physical activity and reducing rates of obesity in our society.2

Azeeem Majeed professor of primary care
University College London, London WC1H 9QU
a.majeed@ucl.ac.uk

Angela Newnham senior lecturer in public health medicine
Thames Cancer Registry, King’s College, London SE1 3QD

Ronan Ryan research officer
Office for National Statistics, London SW1V 2QQ

Kamlesh Khunti senior lecturer in general practice
Department of General Practice, University of Leicester, Leicester LE5 4PW


Let’s move upstream to obesogenic environments, please

Editor—Another BMJ brings yet another editorial on obesity and associated diabetes.1 Once again there is no reference to the real cause of this problem—obesogenic environments.

Why is it that commentators constantly shy away from digging deeper? Why do they repeatedly refuse to venture upstream? It must be blindingly obvious to everyone by now that there is, and never will be, any conventional medical treatment for obesity or diabetes. Doctors should come clean and tell patients and populations that the cure lies not with medicine but in how our societies are created.

Children are denied vital play space because politicians favour selling play space to developers. Sixty per cent of the green space used for housing in London in the past 10 years came from the sale of playing fields (Open spaces conference, Bankside Trust, London, March 2002). We exclude children’s play from our streets by permitting a 30 mph urban speed limit. If we are to encourage an extra 3 miles of walking daily to enable 4 kg weight loss, reducing the risk of developing diabetes by 58%, then we must create an environment where people are able to walk. It is facile and cruel just to tell people that they must walk more. Healthy people need healthy environments.

Politicians have the central role in creating healthy populations. They should stop pandering to powerful lobbies such as the pharmaceutical, motorizing, food, and tobacco industries. If we as doctors do not tell them that they have the prime responsibility for health then we will continue to abuse us by heaping us with impossible responsibilities for changing the health of our nation. When we inevitably fail then they will give us the blame.

General practice in the United Kingdom is currently tittering on the brink of such stupidity in the shape of a new medical contract that will enslave us into performing the impossible tasks of reducing blood pressure/weight/glycated haemoglobin concentrations/cholesterol concentrations, etc. We will soon be shackled to tick box medical consultations stuffing irrelevant data into computers in a pointless and ever increasing spiral of ineffectual intervention while the good that we can do, but which has never been recognised or rewarded, will simply wither and die.

Perhaps the next obesity and diabetes editorial should be commissioned from a sociologist?

Colin Guthrie general practitioner
14/48 Dumbarton Road, Glasgow G14 9DW
grey_triker@hotmail.com


Many South Asian people probably need pre-diabetes care

Editor—In their editorial Venkat Narayanan et al make a case for the American Diabetes Association’s recommendation to screen for pre-diabetes in people over 45.1 Pre-diabetes is defined as either impaired glucose tolerance (two hour glucose concentration 7.8-11 mmol/l after a glucose load) or an impaired fasting glucose concentration of 6.1-6.9 mmol/l. Those screening positive are at high risk of cardiovascular diseases and diabetes and therefore would be counselled on weight loss and increasing physical activity.

This recommendation has profound implications for the health care of South Asian populations originating in the Indian
subcontinent living in urban settings where pre-diabetes is common.\(^3\)

We reported a secondary analysis of the Newcastle heart project based on age and sex adjustment using the standard population of England and Wales on the prevalence of diabetes and pre-diabetes in those aged 25-74 of South Asian (n=680), Chinese (n=375), and white European origin (n=824). Weighted percentages and unweighted numbers for South Asians show that the prevalence of impaired fasting glucose (158/680) and impaired glucose tolerance (140/680) was 19%. The prevalence of pre-diabetes on either definition was 30.5% (225/680). The prevalence of diabetes based on two hour glucose measures was 20.1% (160/680); on the American criteria, 21.4% (140/680) was 19%. Only 49% (295/680) of the population had normal glucose tolerance. A programme of care for pre-diabetes would be needed for about half of the South Asian population in the 25-74 age group, a formidable task complicated by issues discussed below.

Narayan et al would prioritise screening in those with a body mass index of 25 or more, a marker of excess adipose tissue. Markers of obesity, including body mass index, do not have equivalence across ethnic groups.\(^3\) South Asians in the United Kingdom have slightly lower indices but higher waist:hip ratios and greater skinfold thicknesses. Body mass index is not a good indicator of adiposity in South Asians, and a lower cut-off point for being overweight is necessary.

If interventions are to work people need to perceive risk and benefits accurately. In the Newcastle heart project, South Asian women’s perceptions of their own weight did not match guidelines on being overweight and obese.\(^5\) A substantial proportion of overweight South Asian women perceived themselves to be of normal weight, but women of European origin had the opposite problem. South Asians’ knowledge of the causation and prevention of diabetes and heart disease in nearby South Tyneside was poor.

Finally, lack of physical exercise poses a huge challenge (reference available at bmj.com/cgi/eletters/325/7631/405#2558). Although the task of halting the process of pre-diabetes becoming diabetes is urgent, careful evaluation of screening and interventions is essential.

We thank Dr Nigel Unwin for helpful advice in preparing this letter.

---


---

### Women with gestational diabetes should be targeted to reduce cardiovascular risk

Editor—Sattar and Greer discuss the probability that complications in pregnancy may predispose women to vascular and metabolic disease in later life.\(^1\) The link between pregnancy complications and coronary heart disease remains unexplained. We believe that during pregnancy the hormonal and other stresses provoke cardiovascular and metabolic abnormalities in susceptible individuals, which may recur and become permanent as the patient ages. Many of these are coronary risk factors; disturbances in glucose metabolism, which underlie the development of gestational diabetes, are a good example.

An uncomplicated pregnancy is characterised by obvious changes in lipid metabolism early in pregnancy.\(^2\) These include the formation of small, dense subfractions of low density lipoprotein, an important risk factor for atherosclerosis.\(^3\) These are retained in the arterial intima, are more easily oxidised, and once oxidised are rapidly taken up into macrophages, creating foam cells and atherosclerotic plaques. The additional effect of pregnancy on lipid metabolism in people with diabetes and those at increased risk of developing diabetes may markedly increase cardiovascular risk in these women.

We recently studied three groups of pregnant women: healthy controls (n=17, mean age 29.2 (SD 1.1) years), women with type 2 diabetes (n=12, mean age 32.5 (1.6) years), and women with gestational diabetes mellitus (n=12, mean age 32.8 (1.5) years). Venous blood was taken during each trimester (first, 1-13 weeks; second, 14-27 weeks; and third, 28 weeks to term). Samples were analysed for subfractions of low density lipoprotein (polyarylamide gel electrophoresis) and triglycerides. A score for low density lipoprotein was calculated from the area under the curve for each subfraction; the higher the score, the smaller, denser and more atherogenic the low density lipoprotein particles.\(^4\)

Triglyceride concentrations increased throughout pregnancy in all groups. This was most obvious during the second trimester in women with gestational diabetes (figure). Low density lipoprotein score progressively increased throughout pregnancy, implying the formation of potentially atherogenic lipoproteins. These changes were exaggerated in women with type 2 diabetes but more particularly in those with gestational diabetes (figure).

We found that pregnancy and diabetes have an additive effect on the development of an atherogenic lipid profile. Importantly, this is exaggerated earlier in pregnancy in gestational diabetes. This finding may identify women who are particularly susceptible to the premature development of atherosclerosis. We agree with Sattar and Greer that women with gestational diabetes should be targeted during and after pregnancy with advice on diet and lifestyle to try to modify this excess cardiovascular risk.

---

The global response to mental illness

First line care facilities and support for providers have to be improved

Editor—Thornicroft and Maingay highlight the inadequacy of international responses to mental illness.1 In low income countries the burden of mental illness is amplified by financial insecurity, poverty, and partition of families, if not by violence and war. Prevention in mental health is intimately linked with overall human development. Individual care is also necessary. In some societies religious or traditional healers still provide culturally relevant and socially acceptable responses to problems labelled as mental illness. Nevertheless, mental suffering is manifest among users of modern medical services, where it goes largely unrecognised.

Besides poor availability of drugs, human resources are of utmost importance in understanding the apparent neglect of mental health problems. Doctors and nurses in low income countries are often described as rude to their patients,2 partly because they have low salaries and poor professional perspectives, which affects their morale, self confidence, and dedication.3 Some have problems similar to those of their patients—for example, domestic violence or living with HIV. Some are not prepared to face the emotional burden of listening to patients’ suffering. Adequate professional support is unusual, and dealing with emotions is seldom valued by the organisational culture.4

If health care in low income countries is to be oriented towards more biopsychosocial approaches, efforts have to include improving first line care facilities and support for providers. Well functioning first line facilities are crucial to integrate mental health programmes accessible to the population. This does not rule out specialised services, but these tend to remain concentrated in cities and are often of limited accessibility financially. In the case of mental health services, stigmatisation furthermore limits their acceptability to potential users.

The integration of mental health programmes in first line care facilities should of course not be detrimental to the comprehensive character of the service delivered. The purpose is not to divert available resources to serve a specific programme but to take advantage of the existing relations between a service and a community to widen the scope of responses provided locally. Health care in low income countries is increasingly thought of as a series of vertical programmes, so the need for access to regular health care is crucial, and specific programmes must strengthen general services rather than weaken them. Indeed, mental health programmes may improve first line care. Concerns for mental health are likely to promote listening skills, to foster professional identities of care providers, and to take advantage of the existing relations between a service and a community to allow for easier community involvement in mental health care.

Developing countries have four advantages: most ill people live in the community and are cared for by family members; families continue to feel directly responsible for care and support, which is an advantage in organising services; the lack of an extensive mental health infrastructure (specialists, specialist beds, different professionalists, etc) means that services can be organised using community resources; and greater acceptance of patients by the community allows for easier community involvement in mental health care.

Mental health care has been integrated with primary health care in India and Iran. In India, initiatives began in 1975 and led to the development of a district mental health model (1-2 million population).5 This model has now been implemented in 25 districts and is expected to be extended to 100 districts in the next five years (about 150 million population). In Sri Lanka, the amount of training in psychiatry for undergraduates (two full months) has increased and psychiatry is now an examination subject in the final year. The family movement is taking shape in developing countries, and this is fostering new partnerships.6 Massive disasters such as the Gujarat earthquake and the Orissa supercyclone have led to the development of a community based psychosocial care with community volunteers.7 Similar developments are occurring in many countries of Asia, Africa, and South America.

The development of mental health care faces special challenges in developing countries. These are the need for mental health professionals to shift from a clinical to a public health focus; the development of training materials, case records, information systems, and treatment guidelines; the development of support programmes for families; the passing of legislation to protect the rights of mentally ill people and increase access to mental health care; and the availability of adequate numbers of mental health professionals to support, supervise, and guide the new initiatives.

In conclusion, the global situation is a challenge to professionals to think innovatively.

R Srinivasa Murthy professor of psychiatry
Institute of Tropical Medicine, Public Health Department, National Institute, 155, 3000 Antwerp, Belgium


Discontinuation of thioridazine

Risks must be balanced

Editor—Until the Committee on the Safety of Medicines restricted the use of thioridazine in 2000, it was the most widely used antipsychotic drug in the United Kingdom, with 50 million years of safe use by patients worldwide. In Scotland in 1999, were 250 808 were prescriptions dispensed in primary care (hospital data not available, but the safety committee reports that it was the most widely used antipsychotic drug in hospitals too). This dropped to 39 177 in 2001, according to information from the Primary Care Information Unit in Edinburgh.

Is thioridazine safer, cheaper, and more effective than alternative antipsychotic drug treatments for anxiety, agitation, mania, and hypomania? We do not have enough evidence to answer this because thioridazine has been widely used for 30 years—before the days of rigorous randomised controlled trials. Lack of evidence is not evidence of no benefit. Conversely, there is only evidence of a handful of adverse cardiac events, some of which may not have been directly caused by thioridazine or may have been due to combination with other drugs. Although the reported cardiac deaths are lamentable, it


BMJ VOLUME 325 26 OCTOBER 2002 bmj.com
seems that thioridazine is much safer than other effective drugs such as aspirin, which continues to be sold over the counter. Even if adverse events are under-reported, there is far more practical evidence of long term safety for thioridazine compared with much more expensive and much less tried and tested drugs. A recent study noted that many new drugs have a high rate of serious side effects which go undetected until late in postmarketing surveillance. The Committee for the Safety of Medicines needs to balance these relative risks.

The manufacturers of thioridazine have raised few objections to the restricted use of thioridazine because it is an extremely cheap drug, costing only a few pence compared with newer antipsychotics that may be up to a hundred times more expensive, as well as having different and sometimes distressing side effects. The prescription costs of antipsychotic drugs has risen sharply in Scotland in the past two years.

Anecdotally, considerable numbers of patients with hypomania, anxiety, and agitation are having considerable problems in adjusting to a change of drugs, and, as Davies et al point out, informed consent may be a problem. It would be very helpful if the National Institute for Clinical Excellence or Health Technology Board for Scotland reviewed the evidence, risks, and benefits of thioridazine, and considered more humane guidelines for its future use. It seems quite wrong to deprive so many patients of a well tried drug.

Ann F Bisset medical adviser
Public Health Medicine, Information and Statistics Division, Edinburgh EH5 1SQ
Ann.bisset@virgin.net

Competing interests: None declared.

2 Lasseter KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and subsequent testing of prescribed drugs. A recent study noted that many new drugs have a high rate of serious side effects which go undetected until late in postmarketing surveillance.

What happened to thioridazine?
Editor—The article by Davies raised some important issues on discontinuation of thioridazine in populations with learning disability. We had successful withdrawal of thioridazine in our services in Salford district.

We looked at the following issues before withdrawal of thioridazine:

1) Initial diagnosis before thioridazine was prescribed
2) Duration and dose of treatment
3) Review of previous psychiatric treatment including attempts to reduce or stop thioridazine.

Results indicated that 28 out of 175 patients under the care of a psychiatrist specialising in learning disability received thioridazine. Twenty three patients received small doses (50-100 mg) for many years. The main indication for use was marked challenging behaviour (12 patients). Based on the above information, a decision was made to gradually reduce (12 patients) or suddenly stop thioridazine (16 patients).

As an alternative, a tranquiliser was prescribed for all 28 patients. Risperidone was the most commonly used atypical antipsychotic drug because of some evidence of its effectiveness in challenging behaviour. A review of patients’ mental state three months after the substitution of tranquillisers indicated that twenty one patients either remained stable or improved, and seven patients deteriorated. These seven patients subsequently improved, either by a change to a different psychotropic drug or by adjusting the dose of existing drugs. No patient needed to restart taking thioridazine.

Review of previous psychiatric treatment helped us to identify instances of rebound increase in behavioural problems when thioridazine was stopped. It also prompted us to avoid using neuroleptics that were either ineffective or caused unacceptable side effects. Evidence of rebound aggression on stopping neuroleptics was also observed by Mos et al. This lead us to withdraw thioridazine gradually in most cases.

In our opinion risk associated with the withdrawal of thioridazine was managed carefully and minimised by taking into account the diagnosis, the dose and duration, and consequences of previous reduction in medication followed by a careful strategy of either gradual reduction or sudden stoppage with replacement of alternative tranquilisers in appropriate doses.

Pernia Arshad consultant in learning disability
psychiatry
sridhar777@yahoo.co.uk
Mary Moreo senior house officer in psychiatry
Baskaran Sridharan specialist registrar in psychiatry
Department of Psychological Medicine, Meadowbrook Unit, Salford M6 8HG

Competing interests: None declared.


Temple healing

Healing temples may breed superstitions

Editor—Raguram et al report that when patients with psychiatric disorders stay briefly at a healing temple most of them improve significantly. They describe at length the legend of Muthuswamy and endorse the local notion that the temple is endowed with mysterious healing power.

This suggestion could leave unwary patients with an unjustifiably favourable impression that healing temples can cure their diseases. Most Indians are deeply religious and superstitious. In Indian villages myths, misconceptions, blind beliefs, and superstitions abound. Quacks and local healers thrive on the illiteracy and ignorance of naive and gullible people and try to hoodwink them into believing that they have magic cures for their ills.

Muthuswamy temple might be an exception, for it does not charge people who stay there, and, more importantly, offers no specific healing rituals. But local newspapers and quacks may distort the conclusions of the study by pointing out that even a Western journal recognises—and endorses—the hidden healing powers of Indian temples. The news might make thousands of people seek a cure for their chronic diseases in temples and shrines. Even people with potentially curable diseases may choose not to see doctors in the hospitals but seek shelter in holy places. The consequences of such an attitude could be terrible.

History tells us that when tuberculosis was a formidable foe in the 19th century people thought that their best chance of conquering the disease was residing in a sanatorium. Patients and their doctors all over the world believed that a salubrious environment, clear mountain air, and nutritious food was the best way to ensure cure. Thousands of patients with tuberculosis chose Switzerland as their health destination. Myths were woven around sanatoriums, and people who could afford it resided in what they considered “magic mountains” for as long as 10 years.

The sanatorium made most patients feel better for a while, but their infection progressed unabated and killed all of them. Doctors and lay people took 75 years to realise that sanatorium was a highly expensive—and terribly ineffective—intervention for getting rid of tuberculosis.

I think healing temples for alleviating psychiatric disorders and magic mountains for curing tuberculosis share one thing: a strong placebo effect fostered by local superstitions and traditions. Patients with chronic and psychiatric diseases often do not go to their doctors, but we should avoid creating an impression among the public at large that healing temples are capable of restoring their health.

S P Kalantri professor of medicine
Mahatma Gandhi Institute of Medical Sciences,
Sevagram 442102, India
sp_kalantri@rediffmail.com

Muthuswamy temple
Spiritual care is important

Editor—As a senior house officer in an acute psychiatric ward in central London, I can understand why there was improvement in the condition of the psychiatric patients who resided in the Muthusamy temple in India, as reported by Raguram et al. Patients were brought into a place of “refuge” with people similar to them, who understood their condition. This would result in less expressed emotion and distress and better care of the individual, not only by relatives but also by temple staff in a supportive, non-threatening environment. Here people can make sense of their mental illness. This is good “psychiatric” psychiatric care.

How does this contrast with an acute psychiatric ward? Patients are placed in a busy and emotionally charged environment with others who may be more disturbed, usually with little support from relatives. Relatives’ visiting rights are limited, and patients may not have anyone to confide in. Here, the best is good “biological” psychiatric care, with emphasis on psychotropic drug treatment.

What is the way forward? We need a more holistic approach to inpatient psychiatric care to try to “heal” our patients, rather than just treat their psychopathology. Family members need to be fully involved. For serious mental illness, the individual’s spiritual needs, which are important to most people, must be looked after. The power of cultural beliefs and spirituality is important, as seen in the case report of temple healing from India. How does this contrast with an acute psychiatric ward? Patients are placed in a busy and emotionally charged environment with others who may be more disturbed, usually with little support from relatives. Relatives’ visiting rights are limited, and patients may not have anyone to confide in. Here, the best is good “biological” psychiatric care, with emphasis on psychotropic drug treatment.

Is the result increased stigmatisation of psychiatric wards, which are viewed more as places of containment than refuge?

What would have happened if Raguram et al distributed psychotropic drugs to the patients at the temple? I am sure their condition would improve more quickly as there would be “holistic biopsychosocial healing.” I hope for the day when psychiatric wards, which are viewed more as places of containment than refuge.


Primary prevention strategies for cardiovascular disease

Editor—The assumptions made by Marshall and Rouse in their study are too broad and may lead to erroneous conclusions. Using the Framingham equation with average values is going to stratify the population only by age, sex, and diabetes status. Such stratification is simplistic and will prove only that older people and people with diabetes are more at risk. By assuming the subjects are non-smokers Marshall and Rouse exclude the most important single weighting in the Framingham calculation. Most practices have a register of smoking status for most of their patients, so this should be included.

Marshall and Rouse admit that their method may not be able to screen all of the population, so some will lose out. By concentrating on the oldest patients and patients with diabetes first, it will not detect some who have most to lose, such as 50 year old smokers with hypercholesterolaemia and hypertension. Adding a few extra years to the life of a 70 year old non-smoking normotensive diabetes patient may be laudable, but just because it is easier and cheaper does not mean that these patients should be prioritised to be assessed first, as this method seems to suggest.

Many of Marshall and Rouse’s other assumptions do not fit well with the day to day realities of general practice. Few general practitioners would be able to stabilise anti-hypertensive treatment with only four prescriptions and two follow up consultations in a year. Government policy is to issue 30 days’ supply, so Marshall and Rouse underestimate dispensing costs. Not all of this work can or should be done by practice nurses. Other diagnoses will be found requiring medical intervention, and many patients need more careful clinical assessment than a simple protocol provides. Marshall and Rouse’s assumption that two 20 minute consultations by a practice nurse are all that is needed to treat is wrong, so their economic argument is flawed.

Their conclusion about statins and angiotensin converting enzyme inhibitors costing more, so strategies avoiding these may allow more disease to be prevented is odd. It would be actionable to omit a cholesterol measurement on a high risk patient or if a high level was found, negligent not to treat. Avoiding them is not an option in the real world. This paper adds little to the subject other than confusing people into thinking there is a quick and cheap method of cutting short the hard and expensive, but necessary, work of finding all those at risk of heart disease and lengthening their lives.

Gill Tyrerman general practitioner
Peter Tyrerman general practitioner
Rotherham Road Surgery, Barnsley S71 1UT
Trefor J Roscoe general practice informatics tutor, North Trent Institute of General Practice, Northern General Hospital, Sheffield S7 1AU

Resource implications and health consequences of cardiovascular disease prevention with Tyerman et al’s suggestions

<table>
<thead>
<tr>
<th>No of patients assessed</th>
<th>No of patients eligible for any drug treatment</th>
<th>Workload (h)</th>
<th>Benefit: CVD events prevented per 5 years</th>
<th>Cost per 5 years (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assessment clinic</td>
<td>Follow up clinic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>100 75</td>
<td>50 6</td>
<td>9.2</td>
<td>222 967</td>
</tr>
<tr>
<td>200</td>
<td>113 200</td>
<td>75 9</td>
<td>10.3</td>
<td>269 687</td>
</tr>
<tr>
<td>300</td>
<td>135 300</td>
<td>90 10</td>
<td>10.8</td>
<td>301 994</td>
</tr>
<tr>
<td>400</td>
<td>147 400</td>
<td>98 10</td>
<td>11.2</td>
<td>389 099</td>
</tr>
</tbody>
</table>

CVD=cardiovascular disease.

Risk:benefit ratio is important in treating atopic dermatitis

The authors have received funding from Fujisawa and Novartis to advise on and carry out clinical studies on tacrolimus and pimecrolimus.

1 Williams H. New treatments for atopic dermatitis BMJ 2002;324:1533-4

Using evidence based tools to manage chronic illness

The authors have received funding from Fujisawa and Novartis to advise on and carry out clinical studies on tacrolimus and pimecrolimus.

1 Williams H. New treatments for atopic dermatitis BMJ 2002;324:1533-4
Criticism of new German chronic disease management is unfair

Dwana M Bush
family physician
Integrative Health Institute/Atlanta Family Medicine, Atlanta, GA 30342, USA
dbushi@integrativehealth.com

Patient education is not a treatment modality

Jeremy J Jones
consultant rheumatologist
Ysbyty Gwynedd, Bangor, Gwynedd LL57 2PW
jeremy.jones@nww-tr.wales.nhs.uk

1 Von Koff M, Glasgow RE, Sharpe M. ABC of psychologi-
cal medicine: organising care for chronic illness. BMJ
2002;325:92-4. (15 July.)

2002;325:356. (17 August.)

1 Riemsma RP, T aal E, Kirwan JR, Rasker JJ. Patient
education programmes for adults with rheumatoid arthri-

1 Riomsma RP, Taal E, Kirwan JR, Rasker JJ. Patient
education programmes for adults with rheumatoid arthri-

1 Tuffs A. Chronic disease management programmes are
criticised by doctors. BMJ 2002;325:536. (17 August.)

1 Tuffs A. Chronic disease management programmes are
criticised by doctors. BMJ 2002;325:536. (17 August.)